How has been the historical performance of Alembic Pharma?

Answer:The historical performance of Alembic Pharma shows a trend of increasing net sales and total operating income over the years, with net sales rising from 4,605.75 Cr in Mar'20 to 6,672.08 Cr in Mar'25. The total expenditure has also increased, reaching 5,663.84 Cr in Mar'25, which has impacted the operating profit, which stood at 1,050.79 Cr in Mar'25, up from 882.96 Cr in Mar'19 but lower than the peak of 1,567.57 Cr in Mar'21. Profit before tax has fluctuated, with a notable increase to 706.31 Cr in Mar'25 from 385.51 Cr in Mar'23. However, profit after tax has shown variability, peaking at 1,178.11 Cr in Mar'21 and dropping to 581.14 Cr in Mar'25. The company's total assets have grown to 7,606.90 Cr in Mar'25, up from 5,989.05 Cr in Mar'20, while total liabilities have also increased to 7,606.90 Cr in Mar'25. Cash flow from operating activities has decreased significantly to 87.00 Cr in Mar'25 from 1,463.00 Cr in Mar'21, indicating challenges in cash generation despite rising sales.

Breakdown:
Alembic Pharma's financial performance has demonstrated a consistent growth in net sales, which increased from 4,605.75 Cr in Mar'20 to 6,672.08 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar trajectory, reaching 6,672.08 Cr in Mar'25. However, total expenditure also rose, culminating at 5,663.84 Cr in Mar'25, which influenced the operating profit that stood at 1,050.79 Cr, showing a recovery from previous lows but still below the highs of earlier years. Profit before tax has shown improvement, climbing to 706.31 Cr in Mar'25, while profit after tax has been more volatile, peaking at 1,178.11 Cr in Mar'21 before declining to 581.14 Cr in Mar'25. The company's total assets have increased significantly to 7,606.90 Cr, matching its total liabilities, indicating a balanced financial position. Despite the growth in sales, cash flow from operating activities has notably decreased, highlighting potential liquidity challenges as it fell to 87.00 Cr in Mar'25 from much higher levels in previous years.